A complex of neuroprotective therapy, including a new Russian neuropeptide semax, was used in the treatment of glaucoma patients with normalized ophthalmic tone. Electrophysiological and computer methods of examination demonstrated the advantages of new therapy over traditional neuroprotective treatment for glaucoma. The efficiency is due to pathogenetic activity of semax possessing both neuroprotective and neurotrophic effects.
Authors
Kurysheva, N I; Shpak, A A; Ioĭleva, E E; Galanter, L I; Nagornova, N D; Shubina, N Iu; Shlyshalova, N N